BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 35053202)

  • 1. Site-Specific Proteasome Inhibitors.
    Kisselev AF
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome Inhibitor Drugs.
    Fricker LD
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
    Porras-Yakushi TR; Reitsma JM; Sweredoski MJ; Deshaies RJ; Hess S
    J Proteomics; 2021 Jun; 241():104197. PubMed ID: 33848640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunoproteasome as a target in hematologic malignancies.
    Kuhn DJ; Orlowski RZ
    Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
    Fan Y; You G
    Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1.
    Velez B; Razi A; Hubbard RD; Walsh R; Rawson S; Tian G; Finley D; Hanna J
    Proc Natl Acad Sci U S A; 2023 Dec; 120(51):e2308417120. PubMed ID: 38091293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
    Wang J; Fang Y; Fan RA; Kirk CJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
    Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
    Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.